191 |
The Interactive Transcript Abundance Index [c-myc*p73á]/[p21*Bcl-2] Correlates With Spontaneous Apoptosis and Response to CPT-11: Implications for Predicting Chemoresistance and Cytotoxicity to DNA Damaging AgentsHarr, Michael January 2006 (has links)
No description available.
|
192 |
CROSSTALK BETWEEN CANNABINOID RECEPTORS AND EPIDERMAL GROWTH FACTOR RECEPTOR IN NON-SMALL CELL LUNG CANCERRavi, Janani 21 May 2015 (has links)
No description available.
|
193 |
Roles of microRNAs in TRAIL resistance and tumorigenesis in Non-Small Cell Lung CancerJoshi, Pooja 11 October 2017 (has links)
No description available.
|
194 |
MORTALITY AMONG A COHORT OF SOLVENT-EXPOSED SHOE MANUFACTURING WORKERS: AN UPDATELEHMAN, EVERETT J. 17 April 2003 (has links)
No description available.
|
195 |
Inhibition of mTOR for the treatment and prevention of lung cancerMemmott, Regan 05 August 2010 (has links)
No description available.
|
196 |
Foxm1 is a novel regulator of EMT in fibrosis and cancerBalli, David 25 October 2013 (has links)
No description available.
|
197 |
RhoA as a Potential Target in Lung CancerZandvakili, Inuk January 2015 (has links)
No description available.
|
198 |
Organ development and tumorigenesis: a molecular linkBonner, Allison E. 03 February 2004 (has links)
No description available.
|
199 |
Regional Variation in Lung Cancer Incidence, Screening, Survival, and Tumor Characteristics in OhioAlbani, Thomas John 05 October 2022 (has links)
No description available.
|
200 |
Prospective Development and Validation of a Malignancy Scoring System During Endobronchial Ultrasound Evaluation of Mediastinal Lymph Nodes for Lung and Esophageal Cancer / Clinical Utility of Lymph Node Features during EBUSHylton, Danielle A. January 2018 (has links)
Background: At the time of endobronchial ultrasound (EBUS) staging, ultrasonographic features can be used to predict mediastinal lymph node (LN) malignancy. Predictive tools have been developed, however they have not gained widespread use due to lack of research demonstrating validity and reliability. We sought to develop a novel predictive tool, the Canada Score, capable of predicting malignancy and potentially guide LN biopsy decision making.
Methods: We prospectively analyzed the ultrasonographic features of LNs from patients with NSCLC. Ultrasonographic features were identified by a single experienced endoscopist, this data was used to develop the Canada Score. Pathological specimens were used as the gold standard for determination of malignancy. Videos were then circulated to endoscopists across Canada, who were also asked to identify ultrasonographic features for each LN. Hosmer- Lemeshow test, logistic regression, receiver operator characteristic (ROC) curve, and Gwet’s AC1 analyses were used to test the performance, discriminatory capacity, and inter-rater reliability of the Canada Score.
Results: A total of 300 LNs from 140 patients were analyzed by 12 endoscopists across 7 Canadian centres. Backwards elimination was used to create a multivariate model. Hosmer-Lemeshow test and ROC curves indicated the model was well-calibrated (chi2=11.86, p=0.1567) with good discriminatory power (c- statistic= 0.72 ±0.042, 95%CI: 0.64-0.80). Beta-coefficients were used to create a simplified score out of four. Evaluation of the tool showed that LNs scoring 3 or 4 had odds ratios of 15.17 (p<0.0001) and 50.56 (p=0.001), respectively for predicting malignancy. A score of 4/4 was associated with 99.59% specificity and a positive likelihood ratio of 22.78. Inter-rater reliability for a score ≥ 3 was 0.81 ± 0.02 (95%CI: 0.77-0.85).
Conclusions: The Canada Score shows excellent performance in identifying malignant LN at the time of EBUS. A cut-off of ≥ 3 has the potential to inform decision-making regarding biopsy or repeat/mediastinoscopy if the initial results are inconclusive. / Thesis / Master of Science (MSc) / During lymph node staging for lung and esophageal cancer, specific features of lymph nodes can be seen. Using diagnostic tools these features can be used to predict whether a lymph node is cancerous or benign. However, many of these diagnostic tools are inaccurate or unreliable. To address this, this thesis aimed to develop a novel diagnostic tool based on lymph node features seen during staging procedures and determine its clinical usefulness and application to the wider lung and esophageal cancer population. This thesis also aimed to use improved methods to develop this diagnostic tool such that patient and clinician experiences would be significantly improved. The results of this thesis may contribute to a reduction in the number of repeat procedures required for patients undergoing staging prior to their treatment for lung and esophageal cancers.
|
Page generated in 0.0302 seconds